Impact Factor
Global reach, higher impact
Review Frailty and [177Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer Full text PDF
Research Paper Dual-metallic porphyrinic MOFs with pH/ROS-responsive release for antibacterial and antioxidant therapy of diabetic infected wounds Full text PDF
Research Paper A multimodal pipeline for the identification and diagnostic immunoPET validation of hepatocellular carcinoma targets for radiotheranostic development Full text PDF
Research Paper An αvβ6/αvβ8-targeting peptibody inhibits integrin-dependent TGFβ activation, enables tumor-selective cytotoxic delivery, and synergizes with PD-L1 immune checkpoint blockade Full text PDF
Research Paper Radiocopper in BCMA-targeted immunotheranostics of myeloma Full text PDF
Research Paper Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications Full text PDF
Issue 13; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
- Theranostics is indexed by Science Citation Index (SCI) and MEDLINE. (Full index information)
- Full texts of articles in PubMed Central and Europe PMC. Abstracts in PubMed.
- (For NIH-funded researchers) Save time by submitting your paper to us - this journal is in full compliance with NIH Public Access Requirement.
The prognosis of metastatic castration-resistant prostate cancer is dismal. [177Lu]Lutetium-prostate-specific membrane antigen (PSMA)-617 ([177Lu]Lu-PSMA-617) is the new standard of care for PSMA-positive mCRPC previously treated with ARPI and taxane-based chemotherapy. The efficacy and safety of [177Lu]Lu-PSMA-617 have been confirmed by phase 2 (TheraP [NCT03392428]) and phase 3 (VISION study [NCT02511664] and PSMAfore trial [NCT04689828]) clinical ...